[ad_1]
(KPLC / Gray News) – Legacy Pharmaceutical Packaging LLC. Recalls 40 repacked batches of Losartan USP 25 mg, 50 mg and 100 mg tablets due to a possible process impurity or contaminant in an active pharmaceutical ingredient, according to the FDA.
The FDA has stated that it has detected traces of N-methyl-4-amino butyric acid (NMBA) N-Nitroso. NMBA is a potential carcinogen for humans.
Losartan Potbadium USP is a prescription medication used to treat high blood pressure and congestive heart failure, the FDA says. The products can be returned to the pharmacy.
These products have been distributed by pharmacies nationwide, says the FDA. To date, no adverse events have been reported.
See the full report, including the full list of affected products, here.
Copyright 2019 KPLC via Gray TV Group. All rights reserved.
[ad_2]
Source link
